ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
ROS/pH-Responsive Phenylboronic Acid-Chitosan Nanoparticles Improve Silymarin-Mediated Hepatoprotection After Hepatectomy With Gut-Liver Axis-Associated Responses.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To improve hepatoprotective delivery after hepatectomy, a ROS- and pH-responsive silymarin nanoplatform was constructed using phenylboronic acid-grafted chitosan (Sil@PBACS Nps). The nanoparticles displayed a uniform size of 250-300 nm, high encapsulation efficiency, and favorable colloidal stability. Their release behavior was accelerated under acidic and ROS-enriched conditions, supporting lesion-responsive silymarin delivery. Compared with free silymarin, Sil@PBACS Nps (Nps) exhibited stronger antioxidant activity, with DPPH and ABTS scavenging rates of 92.31% and 73.78%, respectively, together with moderate antibacterial effects against S. aureus and E. coli. The formulation showed good biocompatibility, with hemolysis below 5% and cell viability above 80% in AML-12 and HepG2 cells. In a canine hepatectomy model, oral Sil@PBACS Nps reshaped gut microbial composition and altered fecal metabolites associated with sphingolipid metabolism and the pentose phosphate pathway, while hepatic proteomics indicated pathway-level changes related to oxidative phosphorylation and fatty acid biosynthesis. Further validation of the targeted proteins in the mouse model confirmed the involvement of intestinal barrier-related responses in the mouse model and hepatic inflammatory, bile acid, antioxidant, lipid-metabolic, and apoptosis/recovery-associated pathways in both murine liver tissues. These results suggest that Sil@PBACS Nps facilitate post-hepatectomy liver recovery by integrating stimuli-responsive delivery, redox regulation, and gut-liver axis-associated hepatic protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.